JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

Update: 2024-11-20

Description

JACC Associate Editor Neha J. Pagidipati, MD, FACC, speaks with author Christopher M. Kramer, MD, FACC about this substudy of the SUMMIT trial published in JACC and presented at AHA, demonstrating that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of Four Trials

2024-11-2108:13

JACC - SUMMIT 2024: A Video Interview with Harlan Krumholz and Milton Packer| JACC | AHA 2024

2024-11-2049:31

JACC - Recap of AHA From Harlan Krumholz, Editor-in-Chief

2024-11-2014:48

JACC - Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure

2024-11-2018:09

JACC - Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity

2024-11-2017:23

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

2024-11-2014:01

JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024

2024-11-2010:57

JACC - Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial

2024-11-2010:47

JACC - Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study

2024-11-2006:17

JACC - DanGer Shock trial: The impact of age | JACC | AHA 2024

2024-11-2014:23

JACC - Oxidized Phospholipids and Calcific Aortic Valvular Disease

2024-11-2016:41

JACC - Accelerometer-Measured Sedentary Behavior & Risk of Future Cardiovascular Disease | JACC | AHA 2024

2024-11-2008:00

JACC - P2Y12 Inhibitor Pretreatment in Non-ST Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry

2024-11-2015:45

JACC - Hospital-Cardiologist Integration and Outcomes | JACC | AHA 2024

2024-11-2016:09

JACC - Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022

2024-11-2013:43

JACC - November 26, 2024 Issue Summary

2024-11-1825:07

Associations of Self-reported Race, Polygenic Risk, and Social Determinants of Health with Coronary Heart Disease

2024-11-1810:55

Prevalence and Impact of Recurrent Rejection on Pediatric Heart Transplant Recipients: A PHTS Multi-Institutional Analysis

2024-11-1809:47

ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction

2024-11-1810:45

Clinical implications of Pre-test probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension

2024-11-1814:59

00:00

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

#box-pro-ellipsis-173223823771689{-webkit-line-clamp:2;}JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy